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Background. Hepatocellular carcinoma is one of the leading causes of death for compensated chronic liver dis-
ease. 
Aim. The evaluation of technical success as primary ablation rate, local tumor progression, safety, and long-term 
patients outcome of radiofrequency ablation in single (less than 3.5 cm in diameter) or multiple nodules (up to 3, 
sized less than 3 cm) of hepatocellular carcinoma associated to chronic liver disease without cirrhosis.  
Materials and Methods. 25 consecutive patients, mainly chronic hepatitis C, with surgical unresectable hepato-
cellular carcinoma due to comorbidity or tumor location recruited from a local sonographic screening, were 
treated.  
Results. Primary ablation was obtained in 96% of patients (24 out of 25) and in 93 % of nodules (27 out of 29). 1, 3, 
and 5-year local tumor progression rates after treatment were 4, 14, and 14%. Survival rates at 1,3, and 5-year 
were 92, 72, and 64%. No treatment-related deaths and severe complications were recorded.  
Conclusions. Radiofrequency ablation is effective with 96% of primary ablation with few tumoral recurrence and 
limited morbidity in patients with hepatocellular carcinoma associated with chronic liver disease without cir-
rhosis, it could represent a valid alternative treatment whenever surgical therapy is not safe. 
Key words: Hepatocellular carcinoma; Radiofrequency ablation; Therapy; Survival; Ultrasound; Efficacy, Chronic liver dis-
ease, cirrhosis 
INTRODUCTION 
The risk of hepatocellular carcinoma (HCC) in 
patients with chronic hepatitis C infection is extremely 
high, with an incidence ranging between 2% and 8% 
per year in patients who have developed cirrhosis (1). 
Surveillance programs addressed to the early 
detection of small nodular type HCC in patients with 
chronic liver diseases are increasing the eligibility for 
local or surgical treatments (2,3).  
Radical therapies, feasible in up to 30% of cases, 
include surgical resection, orthotopic liver transplan-
tation (OLT), ultrasound (US) guided percutaneous 
ablation with ethanol injection (PEI), and radiofre-
quency ablation (RFA) (1,4). These different therapeu-
tical options are tailored to each individual patient’s 
needs, taking into account general clinical factors, un-
derlying diseases, tumor staging and nodule location 
within the liver. 
In a small proportion of patients with underlying 
cirrhosis, surgical resection is possible and liver trans-
plantation is considered even more effective (5). Pa-
tients not candidates to surgery are considered eligible 
for percutaneous ablative treatments like RFA, which 
is currently considered the best technique to obtain the 
destruction of the neoplastic nodules (5-11) and is 
cost-effective for patients in waiting list for OLT longer 
than 6 months (12).  
The screening guidelines and the curative thera-
pies indications concern only patients with cirrhosis 
(1,4). However, in the clinical practice, even patients 
with B-viral and C-viral chronic liver disease (CLD) 
without any definite diagnosis of cirrhosis undergo 
surveillance by means of a yearly US (3), as the transi-
tion from bridging fibrosis to cirrhosis cannot be de-
termined clinically and HCC develops with a stepwise 
progression of hepatic fibrosis (13). 
In this group of patients surgical resection is con-
sidered the optimal treatment and it is preferred to 
OLT, which does not show any benefit in terms of Int. J. Med. Sci. 2008, 5 
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survival (14).  
We are not aware of any review in the RFA 
therapy literature focused on the efficacy of RFA for 
HCC associated with CLD without cirrhosis, and cur-
rent guide lines on this topic are limited.  
Aim of this study was to investigate treatment 
with RFA for nodular HCC with no indications for 
surgery or OLT, evaluating ablative efficacy, local 
progression, new lesions onset, safety and survival in a 
cohort of consecutive patients with CLD without cir-
rhosis.  
MATERIALS AND METHODS 
According to our local US screening protocol, pa-
tients with Child A/B cirrhosis and those with 
non-cirrhotic chronic liver disease were evaluated with 
abdominal ultrasound every 6 or 12 months respec-
tively. Among patients with newly diagnosed 
non-resectable HCC (either due to the anatomic dis-
tribution of tumor lesions or comorbidity) and among 
patients not eligible for OLT, those with a single nod-
ule smaller than 3.5 cm or with up to 3 nodules sized 
less than 3 cm were enrolled for RFA. In our policy, 
trans arterial chemo embolisation (TACE) is reserved 
for patients with good liver function having more than 
3 nodules or any nodule at an intermediate stage sized 
more than 3.5 cm. Exclusion criteria were liver cirrho-
sis, eligibility for surgical resection or OLT, and pre-
vious treatments with either PEI or TACE. As in our 
district there is not a liver transplant unit, any possible 
candidate to liver transplant was evaluated in regional 
hospitals having a liver transplant program. Three 
patients with previous hepatic resection were included 
in the study. Written informed consent was obtained 
from all the patients according to the local ethic com-
mittee. No patients refused the proposed treatment. 
PATIENTS AND HCC CHARACTERISTICS 
From July 1st 1997 to June 30th 2006, 200 consecu-
tive patients fulfilling the inclusion criteria were 
treated with RFA : 175 out of 200 with liver cirrhosis, 
and 25 out of 200 (12.5%) without cirrhosis according 
to Knodell’s hystological classification (15,16).  
Pre-treatment assessment was performed before 
each treatment with ordinary liver function tests, 
prothrombine time, alpha-fetoprotein platelets counts, 
abdominal spiral computed tomography, chest X-ray, 
abdominal ultrasound with contrast media when ap-
plicable (Sonovue Bracco Italy). 
  The HCC diagnosis was hystologically con-
firmed in 16 out of 25 patients (64%) in the remaining 
cases the diagnosis was considered consistent with 
HCC according with current guide lines for cirrhosis 
(1). Surgical resection was not possible in 2 cases for 
previous liver resection, in 10 cases for comorbidity, in 
6 cases for difficult sided nodules, in 1 case for refusal, 
in 4 cases due to two nodules in different segments of 
the liver and, in the remaining 2 cases during laparo-
tomy of previously planned resection. 
Patients and HCC main features are summarised 
in Table 1.  
Table 1 Characteristics of patients with hepatocellular carci-
noma (HCC) with chronic liver disease without cirrhosis or with 
CLD without cirrhosis treated with radiofrequency ablation 
(RFA). 
Characteristics  HCC\ CLD without Cirrhosis   
Number (%) 
Number of patients  25 
Sex, females  6 (24) 
70.28±7.07  Age 
range = 55-84 
HCV= 21 (84) 
HBV= 1 (4) 
ETOX= 1 (4) 
Etiology 
Others= 2 (8) 
0-20 = 16 (80 ) 
21-100 = 3 (15 ) 
A-fetoprotein 
 
>100 = 1 (5 ) 
29 (1.04 per patient) 
1 tumor = 21 (84) 
Total numbers of tumors 
2 tumors = 4 (16) 
25.4±6.48 
range = 12-35 
1-20= 8 (32,0) 
Size of main tumor 
>20 = 17 (68,0) 
IPER= 3 (12) 
IPO= 19 (76) 
US pattern 
 of main tumor 
MX= 3 (12) 
Well differentiated= 13  Histology 
Poorly differentiated = 3 
 
 
The pathogenesis of the underlying liver disease 
is reported in Table 1. The etiologies classified as 
“others” were C-virus associated with alcohol abuse (1 
case) and metabolic steatosis (1 case). 
The employed instrumental equipment and pro-
cedure techniques are described in a previous our pa-
per (17). 
All RFAs were performed either by the operator 
with the main experience in PEI (A.S.) or under his 
supervision.  
The surveillance protocol included a primary ab-
lation rate and early treatment response assessment, 
by contrast-enhanced spiral CT performed within 1 
month after the end of the treatment, and a long term 
response evaluation, with alfafetoprotein measure-
ment and hepatic ultrasound performed with or 
without injection of contrast media (Sonovue, Bracco 
Italy) every 3 months and spiral CT performed every 6 Int. J. Med. Sci. 2008, 5 
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months.  
The aim of this monitoring was to detect signs of 
both local tumor progression and new lesions sepa-
rated from the previously treated nodule. Multicentric 
disease was defined as onset of more than 3 nodules or 
portal thrombosis or extrahepatic disease. An in-
tra-nodular/peripheral enhancement at CT scan 
and/or an increased size of the nodule were accounted 
as local progression. In case of local tumor progression, 
if the patient still met the inclusion criteria, RFA 
treatment was repeated, while in case of multicentric 
hepatocellular carcinoma, either TACE or only symp-
tomatic relief care was performed when required. 
The primary effectiveness rate was assessed on 
every single nodule on the basis of the absence of vital 
tumor following 1 or 2 treatment sessions. The tumor 
necrosis was considered complete (complete response) 
when no area of enhancement was seen in the nodule 
or at its periphery on CT scan. A tumor persistence 
(enhancement area in the arterial phase in contrast 
imaging) of 30% or more after up to 2 treatment ses-
sions was considered as incomplete ablation or treat-
ment failure respectively. In case of treatment failure, 
when feasible, either PEI or TACE was performed. An 
ablation zone beyond the borders of the tumor was 
defined as ablation margin.   
STATISTICAL ANALYSIS 
Survival rates were assessed using the Kap-
lan-Meier method. No actual dropout was recorded 
among patients, so that the only dropout event con-
sidered was death. 
For the analysis of new events occurred during 
observation, i.e. local tumor progression, new lesions 
onset, and multicentric disease, a Survival analysis 
with the calculation of new events actuarial probability 
was run.   
The maximum observation time was set to 60 
months (5 years) for all patients, including those un-
dergoing longer observation, in order to avoid differ-
ent weighings. 
RESULTS 
Patients description for sex, age, etiology and size 
of the main tumor, location of tumors, US pattern, and 
alfa fetoprotein values are shown in Table 1.  
Follow up observation time ranged from 6 to 107 
months, but in the statistical analysis the maximum 
observation time was set to 60 months for all patients, 
in order to avoid different weightings. The mean fol-
low up was 35.7 months.  
On patients basis, a complete clinical response 
was obtained in 96% of patients (23 cases after 1 
treatment and one more case after 2 treatments), and a 
partial response was recorded in 1 case, which could 
not be further treated because of the onset of multi-
centric diseases. 
RFA efficacy, defined as primary complete abla-
tion on nodular basis, was 93% (27/29). 
30 treatments were performed in 29 nodules of 25 
patients (1.03 treatments on average per nodule). A 
complete ablation was obtained in 27 nodules (93%), 
26 requiring a single treatment session and the re-
maining one requiring 2 treatment sessions, leading to 
a 100% necrosis. In 3 cases an ablation margin was 
detected.  
Within the observation time, local progression 
occurred in 3 cases (12%) (Fig 1): they were treated 
with RFA (2 cases) or PEI (1 case); 7 out of the 8 new 
lesions were treated with RFA (6 cases) or surgical 
resection (1 case), while no treatment was possible for 
the remaining one due to multicentric disease con-
comitant with bone metastasis. 
 
 
Fig 1 Local recurrence rates for the main tumor in HCC asso-
ciated with CLD without cirrhosis. 
 
The new HCC lesions onset rates after 1, 3, and 5 
years were 4%, 33%, and 41% of patients (Fig 2).  
The 5 year probability to develop multicentric 
disease was 16% (Fig 3). Actuarial survival rates after 
1, 3, and 5 years were 92%, 72%, and 64% (Fig 4). 
During the follow-up period, 7 out of 25 patients 
died. Causes of death were neoplasia propagation (3 
cases, one of which with bone metastasis), myocardial 
infarction (1 case), acute leukemia (1 case), and were 
unknown in the remaining 2 cases. 
Only one major complication, subcutaneous tu-
moral seeding, was recorded: it occurs 24 months after 
treatment and was surgically removed.  
Minor complications were in 5 cases self-limited Int. J. Med. Sci. 2008, 5 
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post-RFA syndrome (fatigue, low level fever and 
flu-like syndrome), transient right shoulder pain in 2 
cases for nodule sited in right sub-diaphragm liver’s 
segment. 
 
 
 
 
Fig 2 Overall actuarial probability curves for new hepatocellular 
carcinoma associated with CLD without cirrhosis. 
 
 
 
 
 
 
Fig 3 Overall actuarial probability curve for multicentric hepa-
tocellular carcinoma after RFA in patients without cirrhosis. 
 
Fig 4 Overall actuarial survival rates in patients with hepato-
cellular carcinoma (HCC) associated to CLD without cirrhosis. 
 
 
DISCUSSION 
The prevalence of HCC association with CLD 
without cirrhosis in our study group (12.5%) is com-
parable with that found in a previous local case-control 
study (18). 
Two recent Japanese reviews about HCC treat-
ment with RFA reported a prevalence of patients with 
CLD without cirrhosis equal to 12% and 18% respec-
tively (8, 19). However, they did not describe the out-
come of this subgroup of patients. We can assume that 
also surgical reviews on this topic found analogous 
prevalence without reporting them. 
In a recent meta-analysis evaluating RFA efficacy, 
factors dependent on the tumor features, such as di-
ameter, pathology, proximity to large vessels, sub-
capsular location, as well as RFA electrodes and other 
physician dependent factors, were considered, but not 
pathology of the surrounding liver tissue (20,21). 
It has been supposed that the cirrhotic tissue 
could enable a better thermal ablation through a spe-
cific mechanism known as oven effect (21, 7). Due to 
fibrosis and increased thickness, the cirrhotic tissue 
around the nodule would work as a thermal insula-
tion, avoiding the dispersion of the heat generated 
around the RFA needle electrode. In the current study 
we found that the HCC nodules primary complete 
ablation rate in patients affected by CLD without cir-
rhosis is very high (96%) and comparable with best 
results reported in literature for cirrhotic patients.  Int. J. Med. Sci. 2008, 5 
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As recently reported for RFA in HCC sized less 
than 3.5 cm, the technical efficacy (complete tumor 
ablation) in 1 or 2 sessions range from 76 % to 96 % of 
nodules, with a mean of 1.2 - 1.4 treatments (22,23,) 
and up to 100 % with a mean of 2.2 treatments on 
nodular basis (24). 
The 5-years survival estimated from a cohort of 
patients with cirrhosis and tumours below 3 cm or 3.5 
cm treated by RF is 40 % and 33% respectively (25,26). 
Recent evidence support percutaneous local ab-
lation therapy for small hepatocellular carcinoma con-
sidered as effective as surgical resection (27,28). 
Data recently reported indicate that RFA can be 
considered the treatment of choice for patients with 
single HCC <or= 2.0 cm, even when surgical resection 
is possible for patients with cirrhosis (28). 
In our group survival rates after 1, 3, and 5 years 
were 92%, 72%, and 64% (fig 4). The incidence of ad-
verse events of RFA shows mortality rates ranging 
from 0.3% to 0.5%, and morbidity rates ranging from 
2.2% to 8.9% (29,30). We had no deaths and few com-
plications without any impact on the outcome. 
Local progression rates vary widely between 2% 
to 60% (20). Shina et al. recorded the lower local pro-
gression rate of 2% at 3 years (24) while in our study 
local progression occurred in 3 cases (12%) (Fig 1). 
The new HCC lesions onset rates after 1, 3, and 5 
years were 4%, 33%, and 41% of patients (Fig 2) less 
than reported for patients with cirrhosis (81% at 5 
years as reported by Lencioni et al (31) and the 5 years 
probability to develop multicentric disease was 16 %. 
(Fig 3) 
At the moment, no other studies of RFA therapy 
of HCC associated with CLD without cirrhosis are 
available and this is a limitation of actual guide lines. 
Our results would need to be confirmed using larger 
groups of patients and prospectively compared with 
patients affected by hepatocellular carcinoma and cir-
rhosis.  
The ideal treatment for HCC associated with 
non-cirrhotic CLD is resection, even in case of large 
tumors. However, in some cases it could not be feasi-
ble or safe, due to the nodule location or to the possible 
comorbidity, and it could even be burdened with an 
excessive mortality risk.  
Our findings suggest that in cases of tumors less 
than 3.5 cm in diameter RFA could be a treatment of 
choice also for patients affected by CLD without cir-
rhosis not surgically resectable. 
 
 
Fig 5. a: Ipoechoic nodule of the VII liver segment in a non 
cirrhotic liver pattern, normal hepatic vein. b: The same nodule 
after RF session. 
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